Comparison of the Effect of Preinterventional Arterial Remodeling on Intimal Hyperplasia after Implantation of a Sirolimus- or Paclitaxel-Eluting Stent

Background: We compared the effect of arterial remodeling on intimal hyperplasia (IH) after the implantation of a sirolimus-eluting stent (SES) and a paclitaxel-eluting stent (PES). Methods: The study population consisted of patients with positive or intermediate remodeling and negative remodeling. Results: Sixty-nine patients had positive or intermediate remodeling and 107 patients had negative remodeling. At follow-up, late loss was significantly larger (0.58 8 0.65 vs. 0.38 8 0.55 mm; p = 0.026) in the patients with positive or intermediate remodeling. The IH volume (22.6 8 26.2 vs. 12.4 8 17.4 mm 3 ; p = 0.002) and the percent IH (12.9 8 14.8 vs. 7.0 8 9.6%; p = 0.002) were significantly higher in the patients with positive or intermediate remodeling. Compared to negative remodeling, the IH volume was higher in the PES patients with positive or intermediate remodeling, but this difference was not noted in the SES patients. Multiple-regression analysis revealed that arterial remodeling was a significant independent variable for predicting IH volume in Received: January 11, 2010 Accepted after revision: March 26, 2010 Published online: June 30, 2010 Tae Hoon Ahn, MD Cardiology, Gil Medical Center, Gachon University of Medicine and Science 1198 Kuwol-dong Namdong-gu, Incheon 405-760 (Korea) Tel. +82 32 460 3046/3674, Fax +82 32 460 3117, E-Mail kangwch @ gilhospital.com © 2010 S. Karger AG, Basel 0008–6312/10/1162–0117$26.00/0 Accessible online at: www.karger.com/crd D ow nl oa de d by : 54 .1 91 .4 0. 80 9 /1 6/ 20 17 8 :1 8: 37 P M Kang /Ahn /Moon /Lee /Han /Shin /Kim / Ko /Choi /Jang /Kim /Oh /Jeon /Yang Cardiology 2010;116:117–122 118 come, these relationships need clarification in the DES era [1–6] . We investigated and compared the effect of preinterventional arterial remodeling (positive or intermediate remodeling and negative remodeling) on IH after the implantation of two different DESs: the sirolimuseluting stent (SES, Cypher; Cordis, Miami, Fla., USA) and the paclitaxel-eluting stent (PES, Taxus; Boston Scientific, Natick, Mass., USA).